On November 6, 2025, US President Donald Trump made the announcement in the Oval Office of the White House in Washington, DC, USA.
Jonathan Ernst | Reuters
President Donald Trump is scheduled to announce the launch of TrumpRx on Thursday. TrumpRx is a direct-to-consumer website that is key to the administration’s efforts to lower prescription drug costs in the United States.
White House press secretary Caroline Leavitt said in a post on X that President Trump and other administration officials will launch the new website Thursday at 7 p.m. ET.
He said millions of Americans will save money through TrumpRx, but it remains unclear whether all patients, especially those with insurance, will see further cost savings by using the site to purchase drugs. TrumpRx is targeting people who are willing to forgo insurance and pay cash, suggesting those with no or limited coverage may benefit the most.
The site is not intended to sell drugs directly to U.S. patients, but will serve as a central hub to direct patients to drug companies that are offering discounts on certain products on their direct-to-consumer sites. for example, Eli Lilly and novo nordisk The company is offering its blockbuster obesity drug at a deep discount to patients who pay cash.
In recent months, the companies and at least 14 other drug companies have been negotiating deals with the Trump administration to join the platform and voluntarily sell certain drugs at discounted prices to Medicaid patients. These landmark deals are part of President Trump’s broader “most-favored-nation policy,” which seeks to tie U.S. drug prices to the lowest prices overseas.
It’s the government’s latest effort to rein in U.S. prescription drug prices, which are on average two to three times higher than in other developed countries and up to 10 times higher than in some countries, according to the public policy think tank Rand Corporation.
In an exclusive interview with CNBC last week, Eli Lilly CEO Dave Ricks said his company was the first drug company to sell an obesity drug directly to patients, and that TrumpRx is “extending that industry-wide” to other drugs.
“We’re all for it,” Ricks said.
Questions about savings
Questions remain about how much savings people can expect to save if they use TrumpRx to buy medicines.
The announced price reductions for certain medicines are structured as significant reductions from the so-called retail suggested prices. For example, under Novo Nordisk’s agreement with the administration, the company’s diabetes drug Ozempic will cost $350 a month on TrumpRx, less than half its list price of about $1,000 a month.
But these list prices are often much higher than what private insurers and government programs ultimately pay for the drug, with rebates, discounts and other concessions, according to researchers at Georgetown’s Medicare Policy Initiative. This suggests that some payers may already have secured prices that are equal to or lower than the newly announced drug discounts under the deal with President Trump.
The researchers cited one study that found the average discount for brand-name drugs under Medicare Part D was about 40% of list price. Meanwhile, the discount rate for Medicaid is over 75%, according to a study by the Congressional Budget Office.
